Nikolai Paul Pace

Dr. Nikolai Paul Pace

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2016 in International Journal of Inflammation
Verified
Journal Article
Open access
PDF file
MRMohsin H. K. Roshan
Mohsin H. K. Roshan
ATAmos Tambo
Amos Tambo
NPNikolai Paul Pace
Nikolai Paul Pace
Toll-like receptors (TLRs) are key players in the pathogenesis of inflammatory conditions including coronary arterial disease (CAD). They are expressed by a variety of immune cells where they recognize pathogen-associated molecular patterns (PAMPs). TLRs recruit adaptor molecules, including myeloid differentiation primary response protein (MYD88) and TIRF-related adaptor protein (TRAM), to mediate activation of MAPKs and NF-kappa B pathways. They are associated with the development of CAD through various mechanisms. TLR4 is expressed in lipid-rich and atherosclerotic plaques. In TLR2−/−and TLR4−/−mice, atherosclerosis-associated inflammation was diminished. Moreover, TLR2 and TLR4 may induce expression of Wnt5a in advanced staged atheromatous plaque leading to activation of the inflammatory processes. TLR9 is activated by CpG motifs in nucleic acids and have been implicated in macrophage activation and the uptake of oxLDL from the circulation. Furthermore, TLR9 also stimulates interferon-α(INF-α) secretion and increases cytotoxic activity of CD4+T-cells towards coronary artery tunica media smooth muscle cells. This review outlines the pathophysiological role of TLR2, TLR4, and TLR9 in atherosclerosis, focusing on evidence from animal models of the disease.

FFFrancesca Farrugia
Francesca Farrugia
AAAlexia Aquilina
Alexia Aquilina
JVJosanne Vassallo
Josanne Vassallo
NPNikolai Paul Pace
Nikolai Paul Pace
Type 2 diabetes mellitus (T2DM) is characterised by insulin resistance and eventual pancreatic β-cell dysfunction, resulting in persistent high blood glucose levels. Endocrine disrupting chemicals (EDCs) such as bisphenol A (BPA) are currently under scrutiny as they are implicated in the development of metabolic diseases, including T2DM. BPA is a pervasive EDC, being the main constituent of polycarbonate plastics. It can enter the human body by ingestion, through the skin, and cross from mother to offspring via the placenta or breast milk. BPA is a xenoestrogen that alters various aspects of beta cell metabolism via the modulation of oestrogen receptor signalling. In vivo and in vitro models reveal that varying concentrations of BPA disrupt glucose homeostasis and pancreatic β-cell function by altering gene expression and mitochondrial morphology. BPA also plays a role in the development of insulin resistance and has been linked to long-term adverse metabolic effects following foetal and perinatal exposure. Several epidemiological studies reveal a significant association between BPA and the development of insulin resistance and impaired glucose homeostasis, although conflicting findings driven by multiple confounding factors have been reported. In this review, the main findings of epidemiological and functional studies are summarised and compared, and their respective strengths and limitations are discussed. Further research is essential for understanding the exact mechanism of BPA action in various tissues and the extent of its effects on humans at environmentally relevant doses.

10 November 2016 in EPMA Journal
Verified
Journal Article
Open access
PDF file
MRMohsin H. K. Roshan
Mohsin H. K. Roshan
ATAmos Tambo
Amos Tambo
NPNikolai Paul Pace
Nikolai Paul Pace
Colorectal cancer (CRC) is the fourth commonest type of malignancy after breast, lung and prostate in the USA and accounts for approximately 49,190 deaths

4 October 2023 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Closed access
RARachel Agius
Rachel Agius
NPNikolai Paul Pace
Nikolai Paul Pace
SFStephen Fava
Stephen Fava

1 January 2019 in Sage Open Medicine
Verified
Journal Article
Open access
MRMohsin Hk Roshan
Mohsin Hk Roshan
YSYan K Shing
Yan K Shing
NPNikolai Paul Pace
Nikolai Paul Pace
Breast cancer is one of the most common malignancies in females. It is an etiologically complex disease driven by a multitude of cellular pathways. The proliferation and spread of breast cancer is intimately linked to cellular glucose metabolism, given that glucose is an essential cellular metabolic substrate and that insulin signalling has mitogenic effects. Growing interest has focused on anti-diabetic agents in the management of breast cancer. Epidemiologic studies show that metformin reduces cancer incidence and mortality among type 2 diabetic patients. Preclinical in vitro and in vivo research provides intriguing insight into the cellular mechanisms behind the oncostatic effects of metformin. This article aims to provide an overview of the mechanisms in which metformin may elicit its anti-cancerous effects and discuss its potential role as an adjuvant in the management of breast cancer.

1 April 2021 in Early Human Development
Verified
Journal Article
Closed access
NPNikolai Paul Pace
Nikolai Paul Pace
JVJosanne Vassallo
Josanne Vassallo
JCJean Calleja-Agius
Jean Calleja-Agius